WILMINGTON, Del. / Oct 27, 2023 / Business Wire / Science magazine announced today that for the sixth consecutive year, Incyte has been named a top five employer based on its annual survey of approximately 6,800 individuals. Incyte ranked second on this year’s list, two spots higher than its 2022 ranking, and was specifically recognized for its loyal employees, social responsibility and treating employees with respect.
Incyte is proud to be recognized as a top employer by Science and seeks to create an environment where innovation, collaboration and respect for each other are prioritized. Incyte is guided by its mission to Solve On. for patients around the world – it is a workplace where problems get solved and lives are transformed. Every Incyte employee plays a role in achieving this goal, and the Company is dedicated to creating an atmosphere where employees can grow and thrive to their full potential.
“For more than 20 years, we have focused on creating a culture that fosters innovation, fuels our mission to Solve On. and inspires and energizes our employees as they pursue advances for patients in need. Recognitions like this one from Science magazine, as well as being named one of America’s 100 Most Loved Workplaces and one of the Most Loved Global Workplaces by Newsweek, mean so much and help us maintain the energy and excitement that motivate us as individuals, and as a company, every day,” said Paula Swain, Executive Vice President, Human Resources, Incyte.
The complete Science magazine Top Employers survey feature, along with individual company rankings, is available in the October 27, 2023 print issue of Science and online: https://www.science.org/content/article/making-happy-workplace-employees.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Last Trade: | US$68.84 |
Daily Change: | 1.78 2.65 |
Daily Volume: | 5,651,580 |
Market Cap: | US$13.260B |
December 17, 2024 November 25, 2024 November 18, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB